Please login to the form below

Not currently logged in
Email:
Password:

JE vaccine approved for marketing in Europe

For the first time the EMEA has granted marketing authorisation for a vaccine for the prevention of Japanese Encephalitis in adults. Novartis Vaccines will market the product as Ixiaro in Europe

For the first time the European Medicines Agency (EMEA) has granted marketing authorisation for a vaccine for the prevention of Japanese Encephalitis (JE) in adults. Novartis Vaccines will market the product as Ixiaro in Europe.

JE, a mosquito-borne flaviviral infection, results in 10,000-15,000 deaths annually and is a potential threat for travellers to Asia. Until now there has been no licensed JE vaccine in Europe, although imported vaccines have been available on a named patient basis. The risk of contracting JE from a short urban visit to Asia is generally given as “extremely low”. However, there have been reported cases among short-stay holiday-makers. The risks for long stays in rural areas during transmission season are higher. 

Dr Andrin Oswald, CEO of Novartis Vaccines and Diagnostics, said: "Asia is a very popular travel destination for Europeans. Since JE is spread by mosquitoes, the threat to travellers is unpredictable and may be underestimated. Vaccination is the most effective preventive measure against the disease and this vaccine will help travellers from Europe to Asia."

JE is prevalent in countries such as India, parts of China, Thailand, Indonesia, Cambodia and Vietnam.

27th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics